Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 5 | 13 | -0,21 % | ||
| TEMPUS AI | 1 | 1 | +0,99 % | ||
| ANAVEX LIFE SCIENCES | 1 | - | +1,31 % | ||
| REGENXBIO | 1 | - | -0,53 % | ||
| BIOGEN | - | 54 | +1,19 % | ||
| AMGEN | - | 27 | -0,10 % | ||
| INCYTE | - | 25 | -0,24 % | ||
| REGENERON PHARMACEUTICALS | - | 22 | +0,16 % | ||
| MONTE ROSA THERAPEUTICS | - | 21 | -3,98 % | ||
| EYEPOINT | - | 20 | +3,37 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| So | Curevac-Aktie rückt in den Fokus: Experten halten Ausschläge für möglich - sofort informieren! | Hebelschein-Spekulant | |||
| So | Tempus AI, Inc. (TEM) Strengthens Precision Medicine with New Tools, Partnerships, and Growth Milestones | 8 | Insider Monkey | ||
| So | Clinical Trial Holds Cast Doubt on Approval Chances of Regenxbio Gene Therapy for Rare Disease | 3 | MedCity News | ||
| So | ANAVEX LIFE SCIENCES CORP kurz vor entscheidendem Ausbruch! | 2 | Maximilian Berger | ||
| Sa | Regeneron (REGN) Draws Higher Target From TD Cowen | 2 | Insider Monkey | ||
| Sa | Is Mirum Pharmaceuticals on a Strong Path to Profitability? | 4 | The Motley Fool | ||
| Sa | Should You Buy BioMarin Pharmaceutical Before Feb. 18? | 6 | The Motley Fool | ||
| Fr | If You Invested $100 In Amneal Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today | 2 | Benzinga.com | ||
| Fr | Tenaya Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Fr | MADRIGAL PHARMACEUTICALS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| Fr | Olema Pharmaceuticals: Aktie fällt nach angekündigtem CFO-Abgang | 3 | Investing.com Deutsch | ||
| Fr | ALUMIS INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| Fr | Olema Oncology: Finanzvorstand Shane Kovacs verlässt das Unternehmen nach sechsjähriger Amtszeit | 3 | Investing.com Deutsch | ||
| Fr | Olema Oncology CFO Shane Kovacs to depart after six-year tenure | 1 | Investing.com | ||
| Fr | Olema Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| Fr | Olema Oncology Announces Departure of Chief Operating and Financial Officer | 118 | GlobeNewswire (Europe) | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| Fr | Design Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| Fr | OmniAb, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Fr | Incyte gibt positive CHMP-Stellungnahme zu Zynyz (Retifanlimab) für die Erstlinienbehandlung von fortgeschrittenem Plattenepithelkarzinom des Analkanals (Squamous Cell Carcinoma of the Anal Canal, SCAC) bekannt | 282 | Business Wire | Vorbehaltlich der positiven Entscheidung der Europäischen Kommission wird Zynyz (Retifanlimab) in Kombination mit Carboplatin und Paclitaxel (platinbasierte Chemotherapie) die erste PD-1-Immuntherapie... ► Artikel lesen | |
| Fr | Regeneron outlines 18 new Phase III studies and expects four FDA approvals in 2026 while advancing EYLEA HD and DUPIXENT growth | 4 | Seeking Alpha |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.